Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
4.860
+0.120 (2.53%)
At close: Aug 13, 2025, 4:00 PM
4.750
-0.110 (-2.26%)
After-hours: Aug 13, 2025, 4:26 PM EDT
Pluri Employees
As of June 30, 2024, Pluri had 118 total employees, including 106 full-time and 12 part-time employees. The number of employees decreased by 16 or -11.94% compared to the previous year.
Employees
118
Change (1Y)
-16
Growth (1Y)
-11.94%
Revenue / Employee
$8,763
Profits / Employee
-$175,542
Market Cap
38.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 118 | -16 | -11.94% |
| Jun 30, 2023 | 134 | -25 | -15.72% |
| Jun 30, 2022 | 159 | -3 | -1.85% |
| Jun 30, 2021 | 162 | 4 | 2.53% |
| Jun 30, 2020 | 158 | -7 | -4.24% |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PLUR News
- 2 months ago - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials - PRNewsWire
- 3 months ago - Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - GlobeNewsWire
- 5 months ago - Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness - GlobeNewsWire
- 6 months ago - Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution - GlobeNewsWire
- 7 months ago - Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition - GlobeNewsWire
- 8 months ago - Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease - GlobeNewsWire
- 9 months ago - Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 9 months ago - BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PRNewsWire